Envision Pharma Group acquires healthcare comms consultancy 90TEN
pharmafile | April 9, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | 90TEN, Envision Pharma Group, pharma
Global healthcare communications consultancy 90TEN has been acquired by Envision Pharma Group, it has been revealed.
90TEN said that it would retain its brand and service offering, bringing its insight-led behavioral science model known as ‘Feel-Think-Do’ to a broad spectrum of Envision Pharma Group’s communications solutions. The partnership aims to enrich Envision Pharma Group’s global reach in medical affairs, including strategic publications planning and delivery, medical strategy and communications, market access, and creative and digital solutions.
It is hoped that, in adding 90TEN’s strengths in behavioral science, creativity, and insight-driven communications, the acquisition will deliver an enhanced service offering to the Group’s global client base.
“We’re delighted to welcome an award-winning healthcare communications consultancy into the Envision Pharma Group family,” said David Thompson, CEO, Envision Pharma Group. “90TEN will add its expertise across new verticals for the group – in corporate communications and public relations, while extending Envision’s current footprint in patient engagement and medical communications with its behavioral science methodology. This move bolsters our industry-leading scientific communications capabilities, and enables us to strengthen our offering to clients across the product life cycle.”
90TEN will be managed from its London headquarters by the existing management team, including co-founders Paul Tanner and Carole North, and Managing Directors Peter Impey and Alison Doughty.
“Today marks an exciting milestone in the evolution of 90TEN,” said Paul Tanner, Chairman, 90TEN. “Envision Pharma Group will provide global support to accelerate our plans to extend into more markets and reach more audiences. Both companies share the same values, which is reflected in the similarities between our passionate, ambitious, and collaborative teams who are dedicated to improving patient outcomes.”
Carole North, CEO, 90TEN added: “We’ve always said, if we partnered with another company it would have to be one that was the right strategic and cultural fit for 90TEN, celebrating everything that is 90TEN and the people who make it so successful. Envision Pharma Group embodies all of this and will allow us to retain our individuality, culture, and entrepreneurial spirit as we continue to deliver life-changing communications.”
Based in London, 90TEN employs around 70 members of staff, and works with over half of the top 20 pharma companies in the world serving clients across Europe and North America. The acquisition of 90TEN will bring the total number of Envision Pharma Group employees to around 800 across 14 offices and four continents.
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …
